Get the Stockscreener App
3.90
8.64%
0.31
Alto Neuroscience Inc stock is traded at $3.90, with a volume of 157.54K.
It is up +8.64% in the last 24 hours and up +39.29% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$3.59
Open:
$3.61
24h Volume:
157.54K
Relative Volume:
0.70
Market Cap:
$105.60M
Revenue:
-
Net Income/Loss:
$-49.81M
P/E Ratio:
-1.8089
EPS:
-2.156
Net Cash Flow:
$-42.93M
1W Performance:
+24.20%
1M Performance:
+39.29%
6M Performance:
+22.26%
1Y Performance:
-63.41%
1-Day Range:
$3.61
$3.93
1-Week Range:
$3.046
$3.93
52-Week Range:
$1.60
$15.04
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
3.90 | 92.33M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Does Alto Neuroscience Inc. show high probability of reboundFed Meeting & Reliable Price Breakout Signals - Newser
Will Alto Neuroscience Inc. stock recover after recent dropWeekly Investment Report & Weekly Top Gainers Alerts - Newser
Applying big data sentiment scoring on Alto Neuroscience Inc.Weekly Investment Summary & Accurate Trade Setup Notifications - Newser
Alto Neuroscience’s Depression Drug Shows Positive Biomarker Results in Phase 2 Trial - Insider Monkey
Live market analysis of Alto Neuroscience Inc.July 2025 Trends & Safe Capital Growth Tips - Newser
Shareholders that lost money on Alto Neuroscience, Inc. - GlobeNewswire
News impact scoring models applied to Alto Neuroscience Inc.2025 Retail Activity & Weekly High Momentum Picks - Newser
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Alto Neuroscience, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your RightsANRO - Morningstar
What high frequency data says about Alto Neuroscience Inc.2025 Market Overview & Breakout Confirmation Alerts - Newser
Is Alto Neuroscience Inc. stock poised for growthQuarterly Portfolio Summary & Weekly High Potential Alerts - Newser
Applying Elliott Wave Theory to Alto Neuroscience Inc.Weekly Loss Report & Safe Capital Growth Tips - Newser
Alto Neuroscience (NYSE:ANRO) Receives Buy Rating from HC Wainwright - Defense World
Has Alto Neuroscience Inc. found a price floorWeekly Trend Summary & Community Trade Idea Sharing Platform - Newser
Published on: 2025-08-19 00:52:21 - Newser
Alto Neuroscience, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; September 19, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire
Alto Neuroscience, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; September 19, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire Inc.
ANRO LAWSUIT ALERT: The Gross Law Firm Notifies Alto - GlobeNewswire
Shareholders SueWallSt in New Class Action Against Alto Neuroscience, Inc.Act Now - Nasdaq
Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation - PR Newswire
The Fragile Valuation of Biotech Innovation: Lessons from Alto Neuroscience's Legal and Market Turmoil - AInvest
Levi & Korsinsky Urges Alto Neuroscience, Inc. (ANRO) Shareholders to Act Before Lead Plaintiff Deadline September 19, 2025 - Barchart.com
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. LawsuitANRO - PR Newswire
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Alto Neuroscience's Strategic Investor Engagement in 2025: A Catalyst for Precision Psychiatry Validation and Valuation Growth - AInvest
SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A - GlobeNewswire
Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
Volume Profile Shows Strong Base for Alto Neuroscience Inc.Trade Analysis Report & Technical Pattern Alert System - Newser
Q3 Earnings Forecast for Alto Neuroscience Issued By Wedbush - Defense World
ANRO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Alto Neuroscience, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Alto Neuroscience class action lawsuit filed by Pomerantz LLP. - AInvest
ANRO LAWSUIT ALERT: Levi & Korsinsky Notifies Alto Neuroscience, Inc. InvestorsLead Plaintiff Deadline September 19, 2025 - ACCESS Newswire
What makes Alto Neuroscience Inc. stock price move sharplyTrade Ideas & Safe Capital Growth Plans - thegnnews.com
What are analysts’ price targets for Alto Neuroscience Inc.July 2025 Patterns & High Yield Equity Trading Tips - thegnnews.com
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Alto - GlobeNewswire
Alto Neuroscience Faces Class Action Lawsuit Over IPO and Stock Sales. - AInvest
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain OfficersANRO - PR Newswire
Using AI based signals to follow Alto Neuroscience Inc.Trend Reversal & Safe Capital Allocation Plans - Newser
Is it too late to sell Alto Neuroscience Inc.Market Risk Report & Smart Allocation Stock Tips - Newser
Automated trading signals detected on Alto Neuroscience Inc.Trade Risk Report & Safe Entry Trade Signal Reports - Newser
Quant Tools Rank Alto Neuroscience Inc. as High Risk High RewardQuarterly Trade Summary & Daily Profit Focused Screening - newsyoung.net
Will Alto Neuroscience Inc. face regulatory challengesInflation Watch & Real-Time Stock Entry Alerts - thegnnews.com
Will Alto Neuroscience Inc. outperform tech stocksJuly 2025 Big Picture & Consistent Growth Stock Picks - thegnnews.com
Securities Class Action Lawsuit Filed Against Alto Neuroscience, Inc. (ANRO)Levi & Korsinsky Represents Shareholders - ACCESS Newswire
ANRO Investors: If You Have Suffered Large Losses Contact - GlobeNewswire
Investors who lost money on Alto Neuroscience, Inc. (ANRO) - GlobeNewswire
Navigating the Risks and Rewards of Leading a Biotech Securities Class Action: Lessons from Alto Neuroscience's ANRO Case - AInvest
Alto Neuroscience Investors May Lead Securities Fraud Lawsuit: Deadline for Lead Plaintiff is September 19, 2025 - AInvest
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit - MarketScreener
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience - Morningstar
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):